Physician profile
John Gatlin
NPI 1912999434
$12,489.17
in general payments reported to CMS, 2019-2025
44 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $957 · 2021: $1,590 · 2022: $1,513 · 2023: $1,988 · 2024: $2,289 · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,633 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,632.55 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,850.72 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $1,633.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,089.54 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $911.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $906.11 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $726.60 | 2022-2025 | |
| Axsome Therapeutics, INC. | $502.53 | 2024-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $474.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $396.71 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $395.63 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Janssen Pharmaceuticals, INC | $387.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.21 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.93 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.55 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $250.76 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gatlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.